Xbrane enlists CR on Chinese ranibizumab

Sweden’s Xbrane Biopharma plans to bring its biosimilar ranibizumab, Xlucane, to the Chinese market through a partnership with local firm CR Pharma, the companies have revealed following the signing of a “non-binding letter of intent”. Announcing the partnership, CR Pharma said it would be responsible for registering and marketing the biosimilar in China, as well as conducting any necessary clinical research.

Sweden’s Xbrane Biopharma plans to bring its biosimilar ranibizumab, Xlucane, to the Chinese market through a partnership with local firm CR Pharma, the companies have revealed following the signing of a “non-binding letter of intent”. Announcing the partnership, CR Pharma said it would be responsible for registering and marketing the biosimilar in China, as well as conducting any necessary clinical research.

Following CR Pharma’s announcement, Xbrane sought to “clarify the situation” by stating that “Xbrane and CR Pharma have the joint...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin